NeurAxis Logo.png
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
August 13, 2024 09:00 ET | NeurAxis, Inc.
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Logo.png
NeurAxis Reports Second Quarter 2024 Financial Results
August 09, 2024 08:00 ET | NeurAxis, Inc.
Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
NeurAxis Logo.png
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
August 05, 2024 09:00 ET | NeurAxis, Inc.
CARMEL, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Logo.png
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
June 07, 2024 09:00 ET | NeurAxis, Inc.
CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Logo.png
NeurAxis Reports First Quarter 2024 Financial Results
May 22, 2024 08:00 ET | NeurAxis, Inc.
CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis Logo.png
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 21, 2024 09:00 ET | NeurAxis, Inc.
CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Logo.png
NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida
May 16, 2024 09:00 ET | NeurAxis, Inc.
CARMEL, Ind., May 16, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Logo.png
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
May 15, 2024 16:30 ET | NeurAxis, Inc.
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Logo.png
NeurAxis Announces New Medical Policy Coverage in North Dakota
April 23, 2024 09:00 ET | NeurAxis, Inc.
CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Logo.png
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
April 09, 2024 16:05 ET | NeurAxis, Inc.
CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...